REM behavior disorder (RBD) is a parasomnia characterized by acting out dreams during REM sleep, caused by failure of the brainstem mechanism that normally produces muscle atonia during REM. Bed partners report being kicked, punched, or shouted at; patients themselves may injure themselves or partners while enacting often-violent dream content.
Clinical presentation: typically begins after age 50, predominantly affects men (about 80%). Episodes involve complex motor behaviors during REM — kicking, punching, jumping out of bed, vocalizing, sometimes injurious behaviors. The dream content is often violent or chase-themed (the brain is generating dream content that the body now physically enacts). Patients have vivid recall of dreams matching their behavior.
The mechanism: normally, descending pathways from the brainstem (specifically pontine nuclei including sublaterodorsal nucleus) actively inhibit motor neurons during REM sleep, producing atonia. In RBD, this inhibitory pathway fails. The dreaming brain produces motor signals; the spinal cord receives them without inhibition; the body acts.
The remarkable clinical implication: RBD is among the strongest known prodromal markers of synucleinopathy. Approximately 80% of patients with idiopathic RBD develop Parkinson's disease, Lewy body dementia, or multiple system atrophy within 10-15 years of RBD onset. The pathway is well-established — alpha-synuclein accumulation in brainstem nuclei produces RBD long before cortical/striatal involvement produces motor or cognitive symptoms.
Diagnosis: polysomnography confirming REM without atonia (electromyography shows muscle activity during REM that should be silent) plus history of dream enactment. Differentiate from non-REM parasomnias (sleepwalking, night terrors — emerge from NREM 3, often with confusion, no dream recall), nocturnal seizures (stereotyped, can occur from any sleep stage), obstructive sleep apnea (movements often related to arousals from airway obstruction).
Treatment:
Safety measures — pad bed frame and floor, move sharp objects from bedside, consider sleeping in separate beds during severe symptoms, lock doors and windows to prevent sleepwalking-like behaviors.
Melatonin 3-12 mg at bedtime — first-line because of safety profile, particularly in older patients. Mechanism unclear but effective in many patients.
Clonazepam 0.25-2 mg at bedtime — effective but cognitive effects in elderly limit use. Long half-life produces daytime sedation. Reserve for inadequate response to melatonin.
Prognosis counseling — sensitive but important. The synucleinopathy risk is substantial and the patient may benefit from knowing:
Increased awareness may lead to earlier recognition of motor or cognitive symptoms.
Clinical trial eligibility for disease-modifying trials targeting prodromal synucleinopathy.
Life planning implications including financial, occupational, family.
Some patients prefer not to know detailed prognostic statistics; others want full information. Personalize the conversation.
Monitoring: annual or biennial neurologic evaluation for emerging motor or cognitive symptoms. Smell testing (UPSIT) — hyposmia often precedes motor symptoms. Sometimes DAT-SPECT imaging in selected patients.
When you encounter a patient with dream enactment behaviors, refer for sleep study to confirm RBD. Treatment of the sleep symptoms; counseling about prognostic significance; longitudinal follow-up. The diagnosis offers an opportunity for earlier recognition of synucleinopathy if it develops.